Category Archives: Testosterone Replacement Therapy

The global Testosterone Replacement Therapy Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Testosterone Replacement Therapy Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Testosterone Replacement Therapy Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Testosterone Replacement Therapy Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Testosterone Replacement Therapy Market.

Leading players of the global Testosterone Replacement Therapy Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Testosterone Replacement Therapy Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Testosterone Replacement Therapy Market. It also provides useful recommendations for new as well as established players of the global Testosterone Replacement Therapy Market.

Final Testosterone Replacement Therapy Report will add the analysis of the impact of COVID-19 on this Market.

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2343252

Major Players:

Endo InternationalAbbVieEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals

Segmentation by Product:

GelsInjectionsPatchesOthers

Segmentation by Application:

HospitalsClinicsOthers

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2343252

the Global Testosterone Replacement Therapy Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during the 2021-2026. The report analyses the global Testosterone Replacement Therapy market, the market size and growth, as well as the major market participants.

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Testosterone Replacement Therapy Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The insight has been added in the report to provide realistic overview of the industry, consist of Testosterone Replacement Therapy manufacturers data, i.e. shipment, price, revenue, gross profit, business distribution, etc., SWOT analysis, consumer preference, recent developments and trends, drivers and restrain factors, company profile, investment opportunity, demand gap analysis, forecast market size value/volume, services and product, Porters Five Models, socioeconomic factors, government regulation in Testosterone Replacement Therapy industry. Market players can use the report to peep into the future of the global Testosterone Replacement Therapy Market and bring important changes to their operating style and marketing tactics to achieve sustained growth.

Global Testosterone Replacement Therapy Market: Competitive RivalryThe chapter on company profiles studies the various companies operating in the global Testosterone Replacement Therapy Market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Testosterone Replacement Therapy Market participants in the past few years to remain ahead of the competition.

Table of Contents

Report Overview:It includes major players of the global Testosterone Replacement Therapy Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Testosterone Replacement Therapy Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Testosterone Replacement Therapy Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Testosterone Replacement Therapy Market by application, it gives a study on the consumption in the global Testosterone Replacement Therapy Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Testosterone Replacement Therapy Market are profiled in this section. The analysts have provided information about their recent developments in the global Testosterone Replacement Therapy Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Testosterone Replacement Therapy Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Testosterone Replacement Therapy Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Testosterone Replacement Therapy Market.

Key Findings: This section gives a quick look at important findings of the research study.

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

See original here:
Trending News 2020 Covid-19 impact on Testosterone Replacement Therapy Market Growth Forecast by Type -2025|Pfizer,Actavis...

A novel lymphatically delivered oral testosterone undecanoate (Tlando) is a fixed-dose, well-tolerated, and effective treatment for hypogonadism with liver health benefits that clearly differentiate it from the potentially hepatotoxic oral methyltestosterone, reported Irwin Goldstein, MD, at the American Urological Association 2020 Virtual Experience.

This innovative product has exciting, paradigm-shifting potential for treating men with low testosterone, said Goldstein, director of Sexual Medicine at Alvarado Hospital in San Diego, California, and clinical professor of surgery at the University of California San Diego.

It offers the opportunity to provide safe, effective, and well-tolerated testosterone replacement through the oral route that is the generally preferred method for medication administration. In addition, available data indicate that it not only avoids the adverse hepatic effects that have historically limited use of oral testosterone, but it improves markers of nonalcoholic fatty liver disease [NAFLD] that is a serious and prevalent condition. Low testosterone (ie, hypogonadism) is common in males with NAFLD.

Methyltestosterone is prone to cause liver toxicity with oral ingestion because it is directly transported to the liver through the portal vein, Goldstein said. In contrast, the lymphatically delivered oral testosterone undecanoate is a nonmethylated prodrug of endogenous testosterone, found in Tlando, that avoids first-pass metabolism in the liver and enters the systemic circulation via the lymphatics.

The safety and efficacy of Tlando for treating men with low testosterone was investigated in the 1-year SOAR trial that included 210 men who received the investigational product and a control group of 105 patients treated with topical testosterone gel.

Results from SOAR showed that the oral testosterone undecanoate was associated with a significantly greater increase in free testosterone levels compared with the topical product, and it improved key mental and sexual domains, reported Goldstein, who was an investigator in SOAR and an earlier dosing study.

Safety data in the study included measurement of liver enzymes and showed that reductions were consistently achieved in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and -glutamyl transferase among men who had elevated levels of those markers of liver injury at baseline. Rates of normalization for those 4 enzymes ranged from 31% for -glutamyl transferase to 67% for alkaline phosphatase.

40% reduction in liver fat at 4 months

Additional data on the liver effects of the novel testosterone undecanoate product were obtained in a smaller separate trial of men with hypogonadism. Using the objective Magnetic Resonance Imaging Proton Density Fat Fraction technique to measure liver fat percentage, it found that after 4 months, men with NAFLD at baseline achieved an approximately 40% reduction in liver fat. In addition, more than 75% of men who entered the study with NAFLD were considered responders to the oral testosterone undecanoate based on achieving a 30% or greater reduction in the percentage of liver fat.

In addition, the percentage of patients categorized as NAFLD-free rose during the study and nearly doubled by its conclusion, increasing from 34% at baseline to reach 63% at 16 weeks.

Interestingly, the higher the baseline body mass index, the greater the reduction in liver fat achieved with Tlando treatment, and it appears that the improvement in liver fat does not appear to be explained by any decrease in body weight, Goldstein said.

Disclosures: Lipocine Inc provided funding for the study. Goldstein is on the consultant/advisory board of Lipocine Inc, does research for AbbVie Inc and Marius Pharmaceuticals LLC, is on the Clarus Therapeutics, Inc speakers bureau, and receives writing support from Endo International.

Visit link:
Novel oral testosterone therapy shows liver health benefits - Urology Times

New Jersey, United States,- A detailed research study on Testosterone Replacement Therapy Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Testosterone Replacement Therapy, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=208345&utm_source=COD&utm_medium=888

Leading Testosterone Replacement Therapy manufacturers/companies operating at both regional and global levels:

Testosterone Replacement Therapy Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Testosterone Replacement Therapy market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Testosterone Replacement Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Testosterone Replacement Therapy Market, By Product

Testosterone Replacement Therapy Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=208345&utm_source=COD&utm_medium=888

Testosterone Replacement Therapy Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Testosterone Replacement Therapy market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Testosterone Replacement Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Testosterone Replacement Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Testosterone Replacement Therapy Market, By Deployment Model

5.1 Overview

6 Testosterone Replacement Therapy Market, By Solution

6.1 Overview

7 Testosterone Replacement Therapy Market, By Vertical

7.1 Overview

8 Testosterone Replacement Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Testosterone Replacement Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=208345&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Labeling Equipment Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Laboratory Analytical Instruments and Consumables Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Laboratory Electronic Balance Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post here:
Testosterone Replacement Therapy Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Testosterone Replacement Therapy Sales Market Overview

The Testosterone Replacement Therapy Sales market report presents a detailed evaluation of the market. The report focuses on providing a holistic overview with a forecast period of the report extending from 2018 to 2026. The Testosterone Replacement Therapy Sales market report includes analysis in terms of both quantitative and qualitative data, taking into factors such as Product pricing, Product penetration, Country GDP, movement of parent market & child markets, End application industries, etc. The report is defined by bifurcating various parts of the market into segments which provide an understanding of different aspects of the market.

The overall report is divided into the following primary sections: segments, market outlook, competitive landscape and company profiles. The segments cover various aspects of the market, from the trends that are affecting the market to major market players, in turn providing a well-rounded assessment of the market. In terms of the market outlook section, the report provides a study of the major market dynamics that are playing a substantial role in the market. The market outlook section is further categorized into sections; drivers, restraints, opportunities and challenges. The drivers and restraints cover the internal factors of the market whereas opportunities and challenges are the external factors that are affecting the market. The market outlook section also comprises Porters Five Forces analysis (which explains buyers bargaining power, suppliers bargaining power, threat of new entrants, threat of substitutes, and degree of competition in the Testosterone Replacement Therapy Sales) in addition to the market dynamics.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=241156&utm_source=JLN&utm_medium=888

Leading Testosterone Replacement Therapy Sales manufacturers/companies operating at both regional and global levels:

Testosterone Replacement Therapy Sales Market Scope Of The Report

This report offers past, present as well as future analysis and estimates for the Testosterone Replacement Therapy Sales market. The market estimates that are provided in the report are calculated through an exhaustive research methodology. The research methodology that is adopted involves multiple channels of research, chiefly primary interviews, secondary research and subject matter expert advice. The market estimates are calculated on the basis of the degree of impact of the current market dynamics along with various economic, social and political factors on the Testosterone Replacement Therapy Sales market. Both positive as well as negative changes to the market are taken into consideration for the market estimates.

Testosterone Replacement Therapy Sales Market Competitive Landscape & Company Profiles

The competitive landscape and company profile chapters of the market report are dedicated to the major players in the Testosterone Replacement Therapy Sales market. An evaluation of these market players through their product benchmarking, key developments and financial statements sheds a light into the overall market evaluation. The company profile section also includes a SWOT analysis (top three companies) of these players. In addition, the companies that are provided in this section can be customized according to the clients requirements.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=241156&utm_source=JLN&utm_medium=888

Testosterone Replacement Therapy Sales Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Testosterone Replacement Therapy Sales market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Testosterone Replacement Therapy Sales Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Testosterone Replacement Therapy Sales Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Testosterone Replacement Therapy Sales Market, By Deployment Model

5.1 Overview

6 Testosterone Replacement Therapy Sales Market, By Solution

6.1 Overview

7 Testosterone Replacement Therapy Sales Market, By Vertical

7.1 Overview

8 Testosterone Replacement Therapy Sales Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Testosterone Replacement Therapy Sales Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=241156&utm_source=JLN&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Airport Snow Removal Equipment Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Airport Stand Equipment Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Airport Tugs Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

More:
Testosterone Replacement Therapy Sales Market Growth Prospects, Revenue, Key Vendors, Growth Rate and Forecast To 2026 - Jewish Life News

New data from phase 3 clinical trials provide further evidence supporting the safety and effectiveness of the first-to-market oral testosterone undecanoate treatment for hypogonadism (Jatenzo), reported Stanton Honig, MD.

Honig presented results for secondary end points from 2 randomized studies comparing the lipoprotein-coated testosterone undecanoate formulation with topical testosterone treatments showing that both the oral and gel products were associated with statistically significant improvements in psychosocial well-being and bone and body composition parameters. Safety analyses showed the oral testosterone undecanoate was associated with a modest increase in blood pressure, which was slightly higher in men with hypertension at study entry than in men with normal blood pressure and that neither the oral nor gel testosterones had any significant effect on liver function test results.

This novel formulation of testosterone undecanoate is a first-in-class oral testosterone replacement that does not have liver issues, said Honig, professor of clinical urology and director, Mens Health, Yale University School of Medicine, New Haven, Connecticut.

Taken twice daily, it provides hypogonadal men with total testosterone concentrations in the mid-eugonadal range. Its safety profile is generally consistent with injectable and topical testosterone preparations, although the product labeling for oral testosterone undecanoate includes a black box warning about the potential for increased blood pressure. The data collected in the oral testosterone undecanoate studies underscore the need to check blood pressure at some point in men who are started on this therapy, especially those who are hypertensive at baseline.

The 2 trials comprised a 4-month study and a 12-month investigation. Eligibility criteria were similar in the 2 trials. Men ages 18 to 65 years (to 75 years in the 12-month study) were included if they had hypogonadism (serum testosterone <300 ng/dL on 2 morning samples approximately 7 days apart), had signs and symptoms consistent with hypogonadism, and were either naive to or underwent washout from testosterone therapy.

The 4-month study randomized 222 men 3:1 to oral testosterone undecanoate 237 mg twice daily or once-daily topical testosterone solution. A total of 325 men were randomized 1:1 to oral testosterone undecanoate 200 mg twice daily or topical testosterone gel in the 12-month trial. Dose adjustments were allowed based on serum testosterone levels.

The 4 treatment groups were similar with respect to demographics and clinical characteristics in terms of baseline age, body mass index, comorbidities (prediabetes, diabetes, and hypertension), and mean baseline testosterone levels. Time-weighted average testosterone concentration increased to reach mid-eugonadal levels in all 4 treatment groups, with values ranging from 425 ng/dL to 524 ng/dL across all 4 study groups.

Data on psychosocial well-being were collected in both trials using the Psychosexual Daily Questionnaire. Results showed statistically significant improvements from baseline to study completion in mood, sexual desire, weekly sexual activity, and sexual energy with and without a partner with both the oral and topical treatments, Honig reported.

General well-being was evaluated in the 12-month study using the 36-Item Short Form Health Survey questionnaire. In the individual domains, statistically significant improvements were achieved in both the oral testosterone undecanoate and testosterone gel group and occurred in physical functioning, physical and emotional role limitation, social functioning, and bodily pain.

Changes in body composition parameters were also investigated in the 12-month study. The results for the oral testosterone undecanoate group showed spine bone mineral density, hip bone mineral density, lean body mass, and fat mass all improved significantly from baseline at 6 months with further improvements achieved at month 12.

Both the oral testosterone undecanoate and topical testosterone treatments were associated with minimal increases in serum prostate-specific antigen. Overall, the oral and topical treatments were associated with an increase of hematocrit in approximately 5% to 6% of patients.

Importantly, there were no clinical events associated with the hematocrit increases in the oral testosterone undecanoate or the testosterone gel group, nor did any patient discontinue treatment because of elevated hematocrit, Honig said.

Changes in blood pressure were followed using ambulatory monitoring. Among men treated with oral testosterone undecanoate, mean changes in 24-hour systolic and diastolic blood pressure were approximately 5 mm Hg and 2.5 mm Hg, respectively. Comparisons between men with and without hypertension at baseline showed that the average change was slightly higher in the hypertensive group.

Honig said, It is unclear whether the blood pressure rise is just for oral testosterone undecanoate or a general class effect, as it has been seen with subcutaneous testosterone preparations as well. Most importantly, both oral testosterone undecanoate and topical gel groups showed no significant changes in liver enzyme measurements over a 12-month period.

Disclosure: Honig is a consultant to Clarus Therapeutics and Endo.

See original here:
QOL and body composition benefits seen with novel oral T treatment - Urology Times

By Jeff Sistrunk

Law360 is providing free access to its coronavirus coverage to make sure all members of the legal community have accurate information in this time of uncertainty and change. Use the form below to sign up for any of our daily newsletters. Signing up for any of our section newsletters will opt you in to the daily Coronavirus briefing.

Law360 (June 9, 2020, 7:00 PM EDT) -- Insurers and policyholders have weighed in on two petitions to centralize disputes over businesses' coronavirus-related losses in multidistrict litigation, with supporters touting the efficiency of consolidation and opponents arguing that differences in companies' policies and claims make an MDL inappropriate.

From early May through last Friday, the Judicial Panel on Multidistrict Litigation received 63 responses to the dueling petitions filed by two groups of policyholder plaintiffs, one seeking to centralize the cases in Illinois and the other asking for them to be centralized in Pennsylvania. The JPML is expected to issue a decision on the petitions after it meets in Boston at the end of July.

Of the responses submitted to the JPML, 20 of them all filed by policyholders support some form of coordination. The other 43, filed by a mix of insurers, policyholders and advocates for both, oppose MDL treatment.

Here, Law360 provides a primer on the debate surrounding the MDL petitions.

The Petitioners' Positions

The MDL push dates back to late April, when two groups of businesses affected by COVID-19 shutdown orders filed petitions with the JPML asserting that the business interruption coverage battles in federal court across the country are well-suited for consolidated or coordinated pretrial proceedings. At the time, fewer than 20 cases were pending in federal district courts nationwide; as of Friday, that number had expanded to at least 140 in more than 30 district courts.

In the first petition, filed April 20, a pair of Philadelphia-based restaurants argued that the availability of business interruption coverage in light of the novel coronavirus would be a key question requiring a uniform answer as the country deals with the economic fallout of the pandemic.

"This issue whether business interruption insurance policies will cover losses incurred by businesses forced to shutter their business as a result of the governmental orders is one of national importance and great significance to the ultimate survival of many businesses," the petitioners said. "Addressing this issue in a uniform manner as opposed to potentially disparate treatment by different courts throughout the country helps to serve one of the main purposes" of multidistrict litigation.

The petition asked that cases be centralized before U.S. District Judge Timothy J. Savage of the Eastern District of Pennsylvania, in Philadelphia, who is already presiding over 17 business interruption coverage cases in his district.

"When you look at the mid-Atlantic region, from New York down to D.C., Philadelphia seems to be a natural location," Richard Golomb of Golomb & Honik PC, one of the firms representing the restaurants, told Law360. "Judge Savage is an experienced MDL judge, and very efficient and no-nonsense. He can move a case like this along the way it needs to be moved."

A day later, a group of policyholders in a slew of proposed class actions pending in multiple states filed a second petition to the JPML.

That petition emphasized the importance of coordinating expert witnesses in the cases, as policyholders will need to present "epidemiological modeling of the spread of the virus in order to ascertain its likely presence and impact."

"If these myriad cases were not coordinated for discovery, thousands of plaintiffs would potentially be seeking to retain the same limited pool of epidemiological modelers," the petition said. "Not only would that competition create a costly logistical nightmare for litigants, but that same pool of experts is also needed to help lawmakers fashion the best policies for dealing with the pandemic."

The second group of petitioners suggested the cases be centralized before U.S. District Judge Matthew F. Kennelly of the Northern District of Illinois, in Chicago, who is overseeing an MDL regarding cardiovascular issues allegedly caused by a testosterone replacement therapy drug.

Adam Levitt of DiCello Levitt Gutzler LLC, which is among the firms representing the second group of petitioners, told Law360 that centralization before Judge Kennelly would best serve the principles of the MDL system's enabling statute.

"The insurance industry has obviously elected to take an industry-wide position to oppose JPML centralization, and to keep things as fragmented as possible because each insurer thinks that keeping things fragmented is more strategically advantageous. At the end of the day, all of the industry responses tried to argue how fragmented this all is," Levitt said. "The insurance industry traffics in creating confusion. We don't think it is an appropriate argument here, nor do we think it is valid."

Supporters' Stances

The petitioners' calls for an MDL attracted 20 supporting briefs from individual companies or groups of policyholders. While the supporters all argued that centralization can help streamline the resolution of the many COVID-19 business interruption cases, they offered diverse views on where the proceedings should be placed and how they should be structured.

Among the 20 briefs, seven backed the choice of the Northern District of Illinois and five favored the Eastern District of Pennsylvania.

In the Illinois camp, for instance, one group of 41 policyholders with cases pending in seven states, dubbed the Truehaven plaintiffs, highlighted the central geographic location of the Prairie State and Judge Kennelly's MDL bona fides. The other supporters of the Illinois proposal plaintiffs in another eight business interruption casesvoiced similar views.

Meanwhile, the proponents of centralization in Pennsylvania comprised of plaintiffs in 38 cases across 11 statesemphasized that Judge Savage is already handling a lot of business interruption cases and that the Eastern District of Pennsylvania has about half as many active cases on its docket as the Northern District of Illinois, 8,704 versus 15,874.

Five other groups of policyholder plaintiffs expressed support for the creation of an MDL based in a single federal court but proposed the respective courts in which they are currently litigating cases. Two groups pitched the Southern District of Florida, and one apiece requested the Western District of Missouri, the Western District of Washington and the Northern District of California.

The remaining three supporting briefs asked the JPML to consider forming not one but multiple MDLs, with cases lumped together either by state, region or insurer defendant.

For example, San Francisco-based children's clothing boutique Mudpie Inc., which is pursuing a proposed class action against a Travelers unit in California federal court, proposed the creation of "a small number of MDLs corresponding with states in which numerous actions, filed by different counsel, are pending before different federal judges in different districts." The retailer said that as of Friday, six states would qualify: California, Illinois, Florida, New Jersey, New York and Texas.

"There are still efficiencies to be gained from an approach to centralization that focuses on litigation hot spots, and the panel should follow that approach to steer such controversies on a prudent course," Mudpie wrote.

Cincinnati-based Belgian restaurant chain Taste of Belgium LLC, which is pursuing a proposed class action against The Cincinnati Insurance Co. in Ohio federal court, suggested it would make sense to create multiple MDLs grouped by insurer, as different insurers' policies may contain substantially different terms.

"All actions brought against a given insurer are based on the same or substantially similar questions of law and fact," Taste of Belgium wrote. "Moreover, transfer will promote the convenience of the parties and efficiency in the pretrial proceedings by eliminating duplicative discovery and the potential for inconsistent rulings, including determinations on class certification."

Opponents' Views

The two MDL petitions also drew strong opposition, with 43 briefs urging the JPML to reject the efforts to combine the nation's business interruption cases.

The insurance industry formed a unified front against centralization. Insurers lodged 29 opposition filings, and the industry's two leading trade groups, the American Property and Casualty Insurance Association and the National Association of Mutual Insurance Companies, also weighed in against an MDL. But a dozen individual policyholders and groups of policyholder plaintiffs also opposed consolidated or coordinated proceedings, as did the nonprofit advocacy group United Policyholders.

The opposition briefs generally argued that an MDL would be an inappropriate vehicle for resolving insurance cases, given the differences in insurers' policy language, policyholders' losses during the pandemic and states' laws on the requirements for business interruption insurance.

In a brief joined by 10 other insurance groups, Chubb Ltd. units Westchester Surplus Lines Insurance Co. and Indemnity Insurance Co. of North America contended that combined proceedings would create a logistical nightmare. They pointed out that, while more than 100 insurers are facing suits around the country, only 5% of them have been named as defendants in more than five actions, and most have been named in only one or two cases.

"Every insurer would need (and have a right) to be heard on every issue including discovery and other pretrial rulings affecting it," Westchester and IINA wrote. "The transferee court could not effectively implement a bellwether process, given the lack of overlapping parties among the cases. Resolution of one case would not resolve any other. The resulting proceeding would be unmanageable and delay would be inevitable."

A Chubb spokesman did not immediately respond to a request for comment.

APCIA and NAMIC similarly argued that an MDL could produce delays.

"In view of the extraordinary circumstances created by the COVID-19 pandemic, the parties, courts, and public would be better served by permitting resolution of these cases in their home courts on their individual merits," the trade groups argued.

James Martin of Zelle LLP, who represents APCIA and NAMIC, told Law360 in a statement, "The brief speaks for itself in setting forth why our clients firmly believe that a nationwide federal MDL is not appropriate for these types of matters."

United Policyholders' brief encapsulated the concerns expressed by the policyholder plaintiffs that filed opposition briefs, asserting that there is no "cookie-cutter" scenario for a business interruption claim over losses tied to the COVID-19 pandemic and saying that forcing smaller companies to litigate in courts far removed from their home states would impose undue financial burdens.

"From the beginning, we have been saying you cannot lump all these together, because the policy language is all over the map, different businesses have unique challenges and losses, and insurance is regulated on the state not federal level," United Policyholders executive director Amy Bach told Law360. "We knew it would be a balancing act between judicial efficiency and fairness, having each case resolved on its merits."

--Editing by Brian Baresch and Michael Watanabe.

For a reprint of this article, please contact reprints@law360.com.

See more here:
A Primer On The Push To Combine COVID-19 Coverage Cases - Law360

NEW YORK, May 5, 2020 /PRNewswire/ -- The transdermal drug delivery system market was valued at US$ 6,063.85 million in 2019 and is projected to reach US$ 8,415.04 million by 2027; it is expected to grow at a CAGR of 4.3% during 2020-2027. The growth of the transdermal drug delivery system market is mainly attributed to factors such as the increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, high cost involved in development of drug delivery systems along with drug failure and recalls of transdermal drug delivery systems are likely to restraint the growth of the market during the forecast years.

Read the full report: https://www.reportlinker.com/p05908673/?utm_source=PRN

Transdermal drug delivery systems are devices containing drug of defined surface area that delivers a pre-determined amount of drug to the surface of intact skin at a pre-predefined rate.The skin as a route for systemic drug administration has become very attractive since the introduction of transdermal therapeutic systems in the form of patches.

The discovery of transdermal drug delivery systems (TDDS) is breakthrough in the field of controlled drug delivery system.Transdermal dosage forms, as an alternative to the conventional dosage form are becoming very popular because of their unique advantages.

Like controlled zero ordered absorption, simple mode of administration and having option to terminate the action in case of adverse effect.So the TDDS makes them desirable for the treatment of chronic diseases where long term treatment is necessary.

According to the Centers for Disease Control and Prevention (CDC) in the 2019, almost 6 in 10 people in the US suffer from at least one chronic disease and 4 in 10 people have two or more chronic diseases.

Cardiovascular (CV) diseases such as atherosclerosis, angina pectoris, and acute myocardial infarction are the major cause of mortality in the whole world owing to the present day hectic lifestyle. As per the data provided by WHO, cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Many medications are commercially available for their treatment but the conventional tablets and capsules are unable to cope up with these situations. This augments the use of novel drug delivery systems providing targeted drug delivery and prolonged drug residence to the affected areas of the cardiovascular system. Novel drug delivery systems started with the platform application involving the introduction of transdermal patches, containing drug particles, were applied on skin. They are believed to offer many advantages over conventional oral therapies. Moreover, sizeable number of anti-hypertensive is undergoing extensive first-pass metabolism, which can be avoided by transdermal therapy. Hence, the adoption of transdermal drug delivery systems is likely to experience rapid adoption, which in turn is propelling the market growth.

Based on type, the transdermal drug delivery system market is segmented into transdermal patches and transdermal semisolids.The transdermal patch segment is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and micro needle patches.

The transdermal semisolids segment is further sub segmented into gels, ointments and sprays.The transdermal patches segment held the largest share of the market in 2019.

Also, transdermal patches is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the market is segmented into pain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications.The hormonal applications segment is further sub segmented into transdermal estrogen therapy and testosterone replacement.

The pain management segment held the largest share of the market in 2019; however, pain management segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the global transdermal drug delivery system market is segmented into hospitals and clinics, home care settings, and others. The hospitals and clinics segment held the highest share of the market in 2019; whereas, the home care settings segment is estimated to register the highest CAGR in the market during the forecast period.

The World Health Organization (WHO), Food and Drug Administration (FDA), NHS (National Health Service), and Centers for Disease Control and Prevention are some of the major primary and secondary sources referred for preparing this report.

Read the full report: https://www.reportlinker.com/p05908673/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View post:
Transdermal Drug Delivery System Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type ; Application ; End User ; and Geography -...

This detailed market study covers androgen replacement therapy market growth potentials which can assist the stake holders to understand key trends and prospects in androgen replacement therapy market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the markets growth potential, which can help investors identify scope and opportunities. The analysis also provides details of each segment in the global androgen replacement therapy market

Get Sample Copy of This Report @https://www.quincemarketinsights.com/request-sample-67631?utm_source=AZ&utm_medium=SG

According to the report, the androgen replacement therapy market report points out national and global business prospects and competitive conditions for androgen replacement therapy. Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for androgen replacement therapy. The androgen replacement therapy market has been segmented by product type (creams/gels, patches, injections, implants, and oral tablets/capsules/gums), by active ingredient type (testosterone, methyl testosterone, testosterone undecanoate, testosterone enanthate, and testosterone cypionate), by distribution channel (hospitals pharmacies, retail pharmacies, and online pharmacies). Historical background for the demand of androgen replacement therapy has been studied according to organic and inorganic innovations in order to provide accurate estimates of the market size. Primary factors influencing the growth of the demand androgen replacement therapy have also been established with potential gravity.

Regional segmentation and analysis to understand growth patterns:

The market has been segmented in major regions to understand the global development and demand patterns of this market.

North America, Europe, and Asia Pacific by region are estimated to dominate the androgen replacement therapy market during the forecast period. These regions have been market leaders for the overall healthcare sector in terms of technological developments and advanced medical treatments. Moreover, the government policies have been favourable for the growth of the healthcare infrastructure in these regions. North America and Europe have an established healthcare infrastructure for product innovations and early adaptations. This is expected to drive the demand for androgen replacement therapy market during the forecast period.

Get ToC for the overview of the premium report @https://www.quincemarketinsights.com/request-toc-67631?utm_source=AZ&utm_medium=SG

The US, Germany, France, UK, Canada, and Spain have been some the major markets in the region. Asia Pacific is estimated to register one of highest CAGR for androgen replacement therapy market during the forecast period. This region has witnessed strategic investments by global companies to cater the growing demand in the recent years. China, Japan, India, South Korea, and Australia are amongst some of the key countries for androgen replacement therapy market in the region. Other regions including Middle East, Europe, and Rest of the World (South America and Africa) are estimated to be emerging markets for androgen replacement therapy market during the forecast period.

This report provides:

1) An overview of the global market for androgen replacement therapy market and related technologies.2) Analysis of global market trends, yearly estimates and annual growth rate projections for compounds (CAGRs).

3) Identification of new market opportunities and targeted consumer marketing strategies for global androgen replacement therapy market .4) Analysis of R&D and demand for new technologies and new applications5) Extensive company profiles of key players in industry.

Make an Inquiry for purchasing this Report @https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-67631?utm_source=AZ&utm_medium=SG

The researchers have studied the market in depth and have developed important segments such as product type, application and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

With an emphasis on strategies there have been several primary developments done by major companies such as AbbVie, Inc., Allergan Plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International Plc, Mylan N.V., Novartis International AG, Pfizer, Inc., Clarus Therapeutics, Ferring Holding SA, Perrigo Company Plc, Acerus Pharmaceuticals Corporation.

Market Segmentation:

By Product Type:o Creams/Gelso Patcheso Injectionso Implantso Oral Tablets/Capsules/Gums.

By Active Ingredient Type:o Hospitals Pharmacieso Retail Pharmacieso Online Pharmacies

By Distribution Channel:o Testosteroneo Methyl Testosteroneo Testosterone Undecanoateo Testosterone Enanthateo Testosterone Cypionate

By Region:

North America Androgen Replacement Therapy Marketo North America, by CountryUSCanadaMexicoo North America, by Product Typeo North America, by Modalityo North America, by Distribution Channel

Europe Androgen Replacement Therapy Marketo Europe, by CountryGermanyRussiaUKFranceItalySpainThe NetherlandsRest of Europeo Europe, by Product Typeo Europe, by Modalityo Europe, by Distribution Channel

Asia Pacific Androgen Replacement Therapy Marketo Asia Pacific, by CountryChinaIndiaJapanSouth KoreaAustraliaIndonesiaRest of Asia Pacifico Asia Pacific, by Product Typeo Asia Pacific, by Modalityo Asia Pacific, by Distribution Channel

Middle East & Africa Androgen Replacement Therapy Marketo Middle East & Africa, by CountryUAESaudi ArabiaQatarSouth AfricaRest of Middle East & Africao Middle East & Africa, by Product Typeo Middle East & Africa, by Modalityo Middle East & Africa, by Distribution Channel

South America Androgen Replacement Therapy Marketo South America, by CountryBrazilArgentinaColombiaRest of South Americao South America, by Product Typeo South America, by Modalityo South America, by Distribution Channel

Reasons to Buy This Report:

o Provides niche insights for decision about every possible segment helping in strategic decision making process.o Market size estimation of the androgen replacement therapy market on a regional and global basis.

o A unique research design for market size estimation and forecast.o Identification of major companies operating in the market with related developmentso Exhaustive scope to cover all the possible segments helping every stakeholder in the androgen replacement therapy

Customization:

This study is customized to meet your specific requirements:

o By Segmento By Sub-segmento By Region/Countryo Product Specific Competitive Analysis

Contact:Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109Pune, Maharashtra 411028Phone: US +1 208 405 2835 UK +44 121 364 6144 APAC +91 706 672 4848Email: sales@quincemarketinsights.comWeb:www.quincemarketinsights.com

ABOUT US:QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Follow this link:
Androgen Replacement Therapy Market potential growth, share, demand and analysis of key players - research... - Azizsalon News

Dr. Thomas OConnor has appeared in a selection of our Generation Iron original films over the years. This is due to the fact that he is a doctor that bridges the gap between muscle and medicine. He was strength athlete in his past, he has taken steroids, and he now has a medical license to treat people for after effects of long term steroid use. For this reason, hes known as The Anabolic Doc. So with that in mind, does he believe theres a safe way to use steroids on a bodybuilding level? In our latest GI Exclusive, Dr. Thomas OConnor explains why there is no safe way to use steroids in bodybuilding.

Dr. Thomas OConnor doesnt want to be labeled as an enemy of steroids. He understands and sympathizes on why a person would decide to take the risk and use steroids. Thats why he dedicates his life to treating these people once side effects appear in later years. He tries to bring real medical research into steroid use in sports while also understanding the position these athletes come from. Hes not a fear monger attacking steroids, hes a doctor trying to be an ally to steroid users even when he has to tell the dangerous truths about the drug.

Thats why you wont hear the Anabolic Doc sweepingly say that bodybuilders shouldnt use steroids. He would never say that. What he will do instead, is explain the very real ramifications of that decision. If a bodybuilder is willing to take the risk, he wont discriminate against them down the road when they come back to him for treatment.

What Dr. OConnor wont accept, is lies about the dangers of steroids. He wont sit and let people believe that steroids are actually not that bad for your health. He makes it plain and clear long term steroid use will have permanent effects on your heath. It will lower your testosterone to the point where it might never come back. This leads to needing testosterone replacement therapy (or TRT) for the rest of a persons life. It can lead to enlarged arteries and enlarged hearts. This can then in turn lead to heart disease and death.

Dr. OConnor will never step down from detailing the truly dangerous risks of steroids. But he leaves the decision to use up to the athlete afterwards. Just like cigarettes, people will make their own decision on how they want to handle long term health.

With all of that being said, we wanted Dr. OConnor to clear the air. Is it possible to safely use steroids in bodybuilding at all? Is there some sort of tips or protocol that can help prevent these long term dangers of use?

The Anabolic Docs answer is a simple one. No. Each body is different. Each drug has different effects on different users. Some people might make it out clean but thats not due to a specific way of use. Its due to luck. There is no medical way to condone the use of steroids safely for sports like bodybuilding. Dr. OConnor believes that the research shows its simply impossible.

You can watch Dr. Thomas OConnors, aka The Anabolic Doc, full statements in our latest GI Exclusive interview segment above!

Read more here:
The Anabolic Doc: There Is NO Safe Way To Use Steroids For Bodybuilding - generationiron.com

Global Testosterone Replacement Therapy Market is an extensive compilation of in-depth analysis, factual assessments, value chain structure, industrial environment, regional analysis, applications, market size, share, and forecast. The report explains historic and current market status to provide comprehension for forthcoming occurrences in the market. The report provides an overall analysis of the market based on types, applications, regions, and the forecast period from 2020 to 2025. It also offers investment opportunities and probable threats in the market based on an intelligent analysis. The research will help you to depict the entire global Testosterone Replacement Therapy market through authentic and reliable estimation.

Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE: https://www.mrinsights.biz/report-detail/236403/request-sample

Competitive Landscape:

The report examines the global Testosterone Replacement Therapy market competition by focusing on leading industry players with information such as company profiles, components, and services offered, financial information of the past years, key developments in the previous years. The study presents the strengths and weaknesses of these companies and provides information about various strategies used by these players. The key strategies used by the leading players such as new products, innovation, expanding business through mergers, acquisitions, and partnerships are highlighted.

The most significant players coated in global Testosterone Replacement Therapy market report: AbbVie, Upsher-Smith, Endo International, Pfizer, Actavis (Allergan), Eli lilly, Teva, Bayer, Mylan, Novartis, Ferring Pharmaceuticals, Acerus Pharmaceuticals, Kyowa Kirin

Scope of The Market Report:

The report offers a forward-looking perspective on different factors driving or limiting the market growth. An exceptionally workable estimation of the present industry scenario has been delivered in the study, and the global Testosterone Replacement Therapy market size with regards to the revenue and volume have also been mentioned. In short, the report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, and recent developments in different regions.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Global Testosterone Replacement Therapy market by Type: Gels, Injections, Patches, Other

Global Testosterone Replacement Therapy market by application: Hospitals, Clinics, Other

READ FULL REPORT: https://www.mrinsights.biz/report/global-testosterone-replacement-therapy-market-growth-2020-2025-236403.html

The Listing Supplies Hints On The Upcoming Pointers:

Business Diversification: Market information about new services, untapped geographies, the latest advances, and also investments.

Assessment: In-depth investigation of plans, services, and manufacturing capabilities of these top players.

Business Intelligence: Comprehensive information on Testosterone Replacement Therapy made accessible the very active players in the global sector.

Product Development/Innovation: Comprehensive information about technology, R&D pursuits, together with brand new product launches out of the global Testosterone Replacement Therapy market.

Market Development: Comprehensive information regarding flourishing emerging markets in which the report assesses the market to get worldwide records

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

The rest is here:
Global Testosterone Replacement Therapy Market Business Outlook with COVID-19 Scenario -AbbVie, Upsher-Smith, Endo International, Pfizer, Actavis...